Skip to main content
. Author manuscript; available in PMC: 2018 Aug 18.
Published in final edited form as: Cancer. 2018 Jun 22;124(15):3181–3191. doi: 10.1002/cncr.31571

TABLE 1.

Sociodemographic, Oncologic, and Treatment Characteristics Stratified by Travel Distance for Treatment

Characteristic Short Distance
N = 62,753
Intermediate Distance
N = 40,644
Long Distance
N = 14,603
P
Variable No. (%) No. (%) No. (%)
Age, y <.001
 <50 10,247 (16.3) 7474 (18.4) 2812 (19.3)
 50-59 20,262 (32.3) 13,543 (33.3) 4837 (33.1)
 60-69 17,225 (27.4) 11,597 (28.5) 4062 (27.8)
 ≥70 15,019 (23.9) 8030 (19.8) 2892 (19.8)
Sex .008
 Male 47,090 (75.0) 30,696 (75.5) 10,843 (74.3)
 Female 15,663 (25.0) 9948 (24.5) 3670 (25.7)
Race <.001
 White 51,496 (82.1) 36,766 (90.5) 13,295 (91.0)
 Black 8894 (14.2) 2622 (6.5) 841 (5.8)
 Other 2363 (3.7) 1256 (3.0) 467 (3.2)
Ethnicity <.001
 Non-Hispanic 55,710 (88.8) 36,973 (91.0) 13,406 (91.8)
 Hispanic 3195 (5.1) 954 (2.3) 306 (2.1)
 Other/unknown 2363 (3.7) 1256 (3.0) 467 (3.2)
Charlson/Deyo Comorbidity Score <.001
 0 49,087 (78.2) 32,087 (78.9) 11,506 (78.8)
 1 10,407 (16.6) 6699 (16.5) 2457 (16.8)
 ≥2 3259 (5.2) 1858 (4.6) 640 (4.4)
Insurance <.001
 Private 26,154 (41.7) 18,358 (45.2) 6002 (41.1)
 Medicare 23,775 (37.9) 14,677 (36.1) 5327 (36.5)
 Medicaid 6801 (10.8) 3511 (8.6) 1491 (10.2)
 Uninsured 3841 (6.1) 2467 (6.1) 997 (6.8)
 Other 2182 (3.5) 1631 (4.0) 786 (5.4)
Education, quartiles <.001
 Highest 14,671 (23.5) 8193 (20.2) 1835 (12.6)
 Second highest 19,699 (31.4) 13,258 (32.6) 4781 (32.7)
 Second lowest 16,767 (26.7) 11,757 (28.9) 4944 (33.9)
 Lowest 11,502 (18.3) 7401 (18.2) 3024 (20.7)
 Unknown 24 (0.0) 25 (0.1) 19 (0.1)
Income, quartiles <.001
 Highest 18,638 (29.7) 12,199 (30.0) 1556 (10.7)
 Second highest 16,228 (25.9) 11,235 (27.6) 3253 (22.3)
 Second lowest 14,393 (22.9) 10,195 (25.1) 5383 (36.9)
 Lowest 13,441 (21.4) 6952 (17.1) 4373 (29.9)
 Unknown 53 (0.1) 63 (0.2) 38 (0.3)
County type <.001
 Metropolitan 58,821 (93.7) 28,752 (70.8) 6334 (43.4)
 Urban 2632 (4.2) 9832 (24.2) 6807 (46.6)
 Rural 47 (0.1) 1265 (3.1) 1157 (7.9)
 Unknown 1253 (2.0) 794 (2.0) 305 (2.1)
Site <.001
 Oral cavity 14,072 (22.4) 11,516 (28.3) 5980 (41.0)
 Oropharynx 23,563 (37.5) 15,178 (37.3) 4603 (31.5)
 Hypopharynx 3374 (5.4) 1744 (4.3) 504 (3.5)
 Larynx 21,744 (34.7) 12,206 (30.0) 3516 (24.1)
AJCC clinical stage grouping <.001
 I 15,639 (24.9) 10,229 (25.2) 3289 (22.5)
 II 9630 (15.3) 6274 (15.4) 2363 (16.2)
 III 11,704 (18.7) 7299 (18.0) 2462 (16.9)
 IV 25,780 (41.1) 16,842 (41.4) 6489 (44.4)
Treatment modality <.001
 Surgery 12,147 (19.4) 10,703 (26.3) 6044 (41.4)
 Surgery plus adjuvant 12,490 (19.9) 8707 (21.4) 3864 (26.5)
 Radiotherapy 20,998 (33.5) 10,575 (26.0) 1781 (12.2)
 Chemoradiation 17,118 (27.3) 10,659 (26.2) 2914 (20.0
Facility type <.001
 Community 6190 (9.9) 3408 (8.4) 325 (2.2)
 Comprehensive community 25,535 (40.7) 14,776 (36.4) 2661 (18.2)
 Academic 22,918 (36.5) 17,869 (44.0) 10,179 (69.7)
 Integrated network 6793 (10.8) 3547 (8.7) 972 (6.7)
 Unknown 1317 (2.1) 1044 (2.6) 466 (3.2)
Facility annual volume, quartiles <.001
 1-9 18,505 (29.5) 7920 (19.5) 1022 (7.0)
 >9 to 17 17,808 (28.4) 10,839 (26.7) 1927 (13.2)
 >17 to 43 15,817 (25.2) 10,164 (25.0) 3069 (21.0)
 >43 10,623 (16.9) 11,721 (28.8) 8585 (58.8)
Region of United States <.001
 New England 3915 (6.4) 2118 (5.3) 210 (1.5)
 Middle Atlantic 9980 (16.2) 5035 (12.7) 1164 (8.2)
 South Atlantic 13,883 (22.6) 9826 (24.8) 3097 (21.9)
 East North Central 13,785 (22.4) 7882 (19.9) 2341 (16.6)
 East South Central 3904 (6.4) 4031 (10.2) 1911 (13.5)
 West North Central 3854 (6.3) 3171 (8.0) 2400 (17.0)
 West South Central 3694 (6.0) 2962 (7.5) 1207 (8.5)
 Mountain 2291 (3.7) 1394 (3.5) 780 (5.5)
 Pacific 6130 (3.7) 3181 (8.0) 1027 (7.3)
Year of diagnosis <.001
 2004-2005 10,120 (16.1) 5902 (14.5) 2065 (14.1)
 2006-2007 10,838 (17.3) 6603 (16.2) 2367 (16.2)
 2008-2009 13,032 (20.8) 8183 (20.1) 2943 (20.2)
 2010-2011 13,809 (22.0) 9311 (22.9) 3380 (23.1)
 2012-2013 14,953 (23.8) 10,645 (26.2) 3848 (26.4)

Abbreviations: AJCC, American Joint Committee on Cancer.